Table 2.
Interventionsa.
| Number of patients, n (%) | 319 (100) |
| Endocrine therapy, n (%) | 209 (65.5) |
| Tamoxifen | 142 (44.5) |
| Letrozole | 46 (14.4) |
| Anastrozole | 27 (8.5) |
| Exemestane | 15 (4.7) |
| Other | 6 (1.9) |
| Chemotherapy, n (%) | 87 (27.3) |
| Epirubicin | 65 (20.4) |
| Paclitaxel | 63 (19.7) |
| Cyclophosphamide | 70 (21.9) |
| Biphosphonate | 5 (1.6) |
| Other | 14 (4.4) |
| Immunotherapy, n (%) | 29 (9.1) |
| Trastuzumab | 28 (8.8) |
| Pertuzumab | 3 (0.9) |
| Other | 4 (1.3) |
| Mistletoe therapy, n (%) | 129 (40.4) |
| Subcutaneous | 119 (37.3) |
| Intravenous | 40 (12.5) |
| Abnobaviscum | 71 (22.3) |
| Helixor | 48 (15.0) |
| Iscador | 46 (14.4) |
| Iscucin | 16 (5.0) |
| Other | 3 (0.9) |
a
Characteristics of applied interventions (n = 319). Numbers in columns do not add to 319, as the patients have received various combinations of preparations and applications, respectively.